Your browser doesn't support javascript.
Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano, Makoto; Morita, Yoshifumi; Nakano, Yuki; Yokoyama, Rin; Shimura, Takuya; Qian, Chungen; Xia, Fuzhen; He, Fan; Zheng, Liang; Ohmiya, Hiroko; Kishi, Yoshiro; Okada, Jun; Yoshikawa, Naoyuki; Nakajima, Kazuki; Nagura, Yutaka; Okazaki, Hitoshi; Jubishi, Daisuke; Moriya, Kyoji; Seto, Yasuyuki; Yasui, Fumihiko; Kohara, Michinori; Wakui, Masatoshi; Kawamura, Takeshi; Kodama, Tatsuhiko; Yatomi, Yutaka.
  • Kurano M; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. Electronic address: kurano-tky@umin.ac.jp.
  • Morita Y; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
  • Nakano Y; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
  • Yokoyama R; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
  • Shimura T; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
  • Qian C; The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics - Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and T
  • Xia F; Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, PR China.
  • He F; Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, PR China.
  • Zheng L; Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, PR China.
  • Ohmiya H; Business Planning Department, Sales & Marketing Division, Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
  • Kishi Y; Business Planning Department, Sales & Marketing Division, Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
  • Okada J; Business Planning Department, Sales & Marketing Division, Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
  • Yoshikawa N; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
  • Nakajima K; Department of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan.
  • Nagura Y; Department of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan.
  • Okazaki H; Department of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan.
  • Jubishi D; Department of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan.
  • Moriya K; Department of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan.
  • Seto Y; Department of Gastrointestinal Surgery, The University of Tokyo, Japan.
  • Yasui F; Tokyo Metoropolitan Institute of Medical Research, Tokyo, Japan.
  • Kohara M; Tokyo Metoropolitan Institute of Medical Research, Tokyo, Japan.
  • Wakui M; Department of Laboratory Medicine, Keio University School of Medicine.
  • Kawamura T; Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan; Isotope Science Center, The University of Tokyo, Tokyo, Japan.
  • Kodama T; Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
  • Yatomi Y; Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. Electronic address: yatoyuta-tky@umin.ac.jp.
Int Immunopharmacol ; 103: 108491, 2022 Feb.
Article Dans Anglais | MEDLINE | ID: covidwho-1587489
ABSTRACT
To better understand the immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with COVID-19, it is important to investigate the kinetics of the antibody responses and their associations with the clinical course in different populations, since there seem to be considerable differences between Western and Asian populations in the clinical features and spread of COVID-19. In this study, we serially measured the serum titers of IgM, IgG and IgA antibodies generated against the nucleocapsid protein (NCP), S1 subunit of the spike protein (S1), and receptor-binding domain in the S1 subunit (RBD) of SARS-CoV-2 in Japanese individuals with COVID-19. Among the IgM, IgG, and IgA antibodies, IgA antibodies against all of the aforementioned viral proteins were the first to appear after the infection, and IgG and/or IgA seroconversion often preceded IgM seroconversion. In regard to the timeline of the antibody responses to the different viral proteins (NCP, S1 and RBD), IgA against NCP appeared than IgA against S1 or RBD, while IgM and IgG against S1 appeared earlier than IgM/IgG against NCP or RBD. The IgG responses to all three viral proteins and responses of all three antibody classes to S1 and RBD were sustained for longer durations than the IgA/IgM responses to all three viral proteins and responses of all three antibody classes to NCP, respectively. The seroconversion of IgA against NCP occurred later and less frequently in patients with mild COVID-19. These results suggest possible differences in the antibody responses to SARS-CoV-2 antigens between the Japanese and Western populations.
Sujets)
Mots clés

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Immunoglobuline A / Immunoglobuline G / Immunoglobuline M / SARS-CoV-2 / COVID-19 Type d'étude: Étude observationnelle / Étude pronostique Limites du sujet: Humains Pays comme sujet: Asie langue: Anglais Revue: Int Immunopharmacol Thème du journal: Allergie et immunologie / Pharmacologie Année: 2022 Type de document: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Immunoglobuline A / Immunoglobuline G / Immunoglobuline M / SARS-CoV-2 / COVID-19 Type d'étude: Étude observationnelle / Étude pronostique Limites du sujet: Humains Pays comme sujet: Asie langue: Anglais Revue: Int Immunopharmacol Thème du journal: Allergie et immunologie / Pharmacologie Année: 2022 Type de document: Article